WORK Medical Technology Group LTD
WORK Medical Technology Group is a medical device company whose operations are primarily conducted by its subsidiaries in China. It researches, develops, manufactures and sells medical devices for healthcare providers and other customers, including hospitals, pharmacies and medical institutions. Hangzhou Shanyou handles production and sells Class I and II devices such as endotracheal tubes, breathing circuits, laryngeal mask airways and artery compression tourniquets, as well as hygiene products and disposable medical supplies. Other subsidiaries conduct medical-device research and development or sales, and one sells chemical products. The product portfolio also includes an artificial intelligence automated blood cell morphology analyzer and a visualized prostatic dilatation catheter. The company makes money through its Chinese subsidiaries’ manufacturing and sales of medical devices under their own brands, both domestically and internationally. Its products are sold through distributors in China and exported to more than 30 countries. WORK Medical Technology Group’s principal executive offices are in Hangzhou City, Zhejiang Province, China.
No enriched coverage for $WOK in the last 7 days.
No SEC Form 4 filings for $WOK in the last 30 days.
See all $WOK insider activity →Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.
U.S. stock index futures were mixed late Tuesday, with Nasdaq 100 futures up 0.2% and S&P 500 futures up 0.1%, while Dow futures slipped. Markets weighed hotter inflation, rising Treasury yields and oil after Trump criticized the U.S.-Iran ceasefire. Stocks mentioned include NVDA, SLS, WEN, WOK, RCAT and RVI. PPI and Fed speakers are key Wednesday catalysts.
HRT FINANCIAL LP purchased 880,456 shares of WORK Medical Technology Group LTD (WOK) at $0.05 on 2026-06-17.
Recent WOK coverage spans insider activity, market movers and financial news.
Corporate structure change and reverse split can affect liquidity and perception, but the operational impact is less immediate than clinical/regulatory catalysts.
High-volatility momentum trade driven by new partnership and platform expansion claims.
The filing is a disclosed insider/affiliate buy, but it is small relative to typical institutional flows and lacks a new fundamental catalyst.
Insider/10% owner selling pressure could weigh on sentiment, though it’s not a fundamental catalyst by itself.
Insider/10% owner buying is modestly supportive, but the disclosed dollar value is small and lacks guidance or operational catalysts.
AlphAI scores every news story that mentions WOK with an AI model for sentiment and relevance, and aggregates insider trades from WORK Medical Technology Group LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.
U.S. stock index futures were mixed late Tuesday, with Nasdaq 100 futures up 0.2% and S&P 500 futures up 0.1%, while Dow futures slipped. Markets weighed hotter inflation, rising Treasury yields and oil after Trump criticized the U.S.-Iran ceasefire. Stocks mentioned include NVDA, SLS, WEN, WOK, RCAT and RVI. PPI and Fed speakers are key Wednesday catalysts.
HRT FINANCIAL LP purchased 880,456 shares of WORK Medical Technology Group LTD (WOK) at $0.05 on 2026-06-17.
HRT FINANCIAL LP sold 2,904,567 shares of WORK Medical Technology Group LTD (WOK) at $0.06 ($0.17M total) on 2026-06-16.
HRT FINANCIAL LP purchased 268,927 shares of WORK Medical Technology Group LTD (WOK) at $0.10 on 2026-06-15.
WORK Medical Technology Group (Nasdaq: WOK) said it will conduct a 1-for-100 reverse stock split of its Class A and Class B ordinary shares effective June 18, 2026. Class A shares are expected to trade on a post-split basis that day under symbol WOK with a new CUSIP. It had 241.65M Class A shares outstanding; about 2.42M are expected after the split.
HRT FINANCIAL LP purchased 48,108 shares of WORK Medical Technology Group LTD (WOK) at $0.08 on 2026-06-12.
HRT FINANCIAL LP purchased 3,794,711 shares of WORK Medical Technology Group LTD (WOK) at an average of $0.10 ($0.09–$0.10, $0.36M total) across 2 trades over 2026-06-10 to 2026-06-11.
HRT FINANCIAL LP sold 3,463,022 shares of WORK Medical Technology Group LTD (WOK) at $0.10 ($0.36M total) on 2026-06-09.
HRT FINANCIAL LP purchased 2,261,118 shares of WORK Medical Technology Group LTD (WOK) at $0.11 ($0.24M total) on 2026-06-08.
